Boehringer Ingelheim is one of the world’s leading pharmaceutical companies in the treatment of respiratory diseases. Our central aim is to leverage our longstanding expertise in respiratory medicine to relentlessly target indications with high unmet medical need.

Our Respiratory Diseases Partnering Focus
We are further strengthening our existing portfolio for the treatment of respiratory diseases through in-licensing and external collaborations at research, pre-clinical and clinical stages.

Specific partnering priorities:
- IPF/PF-ILD: Block of pro-fibrotic signaling beyond standard of care
- Chronic Obstructive Pulmonary Disease: Stop/slowdown of small airway diseases
- Asthma: Treatment of severe non-Th2 asthma

Furthermore we are interested in the following research areas:
- Aberrant epithelial sensing
- Epithelial - fibroblast interactions
- Dysregulated macrophage function respiratory diseases

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:
Dr. Silke Hobbie
silke.hobbie@boehringer-ingelheim.com

Dr. Peter Seither
peter.seither@boehringer-ingelheim.com